Haemonetics’ VASCADE MVP® XL Demonstrates Strong Safety and Efficacy in Large-Bore Venous Closure, New Study Finds Haemonetics Corporation a global leader in medical technology solutions aimed at improving patient outcomes, has announced the publication of new clinical research evaluating its…
HCA Healthcare, Inc. Reports First Quarter 2026 Results with Steady Revenue Growth and Strong Cash Flow HCA Healthcare one of the largest healthcare service providers in the United States, has announced its financial and operating results for the first quarter…
Elevance Health Reports Strong Q1 2026 Results and Raises Full-Year Guidance Elevance Health reported first quarter 2026 financial results that exceeded expectations, reflecting strong operational performance, improving claims experience, and continued execution of strategic initiatives. The company also raised its…
The Cigna Group Advances Industry Efforts to Simplize Prior Authorization The has announced a significant step forward in improving healthcare access and administrative efficiency by joining other leading health insurers in a shared commitment to standardize electronic prior authorization submission…
Health Net’s $10 Million Investment to Fast-Track Affordable Housing Development Across Los Angeles County In a significant move aimed at addressing California’s deepening housing crisis, Health Net has announced a $10 million investment in LA4LA’s innovative “Guarantee Fund.” This strategic…
Fulgent Genetics, Inc. Selected for Rapid Oral Presentation in Head & Neck Cancer Track at ASCO Annual Meeting 2026 Fulgent Genetics, Inc., a technology-driven company known for its established laboratory services and expanding therapeutic development pipeline, announced that one of…
Definium Therapeutics Showcases DT120 ODT (Lysergide Tartrate) Progress and Commercial Plans at Investor & Analyst Day Definium Therapeutics, a late-stage clinical biopharmaceutical company, recently provided a comprehensive update on the progress of its lead investigational therapy, DT120 ODT (lysergide tartrate),…
Federal Push Accelerates Psychedelic Therapies as Clinical Infrastructure Races to Keep Up The landscape of mental health treatment development is undergoing a significant transformation as recent federal action signals a stronger commitment to accelerating psychedelic therapies through the regulatory pipeline.…
Treehub by AI Health Fund Launches to Identify Next-Generation Academic and Scientific Founders Treehub, a newly launched Stanford-adjacent residency backed by the AI Health Fund, is positioning itself as a transformative force in healthcare innovation by identifying and supporting early-stage…
Kallyope Reports Promising Phase 2b Results for Elismetrep, Introducing a Novel Mechanism for Acute Migraine Treatment Kallyope, a late-stage biotechnology company dedicated to developing innovative therapies for neurological and metabolic disorders, has announced encouraging results from its Phase 2b clinical…